Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 3,535 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: HIV Infections
Interventions: ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more

Conditions: Rheumatoid Arthritis
Interventions: MORAb-022; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Los Angeles, California • Jacksonville, Florida • Oklahoma City, Oklahoma + 1 more

Conditions: Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions: Sodium Acetate, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus
Interventions: Hemopfin+Green Light, Vehicle+Green Light; Drug · Device
Lead sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Irvine, California • San Diego, California • Miami, Florida + 2 more

Conditions: Alcohol Drinking
Interventions: 21mg transdermal nicotine patch (Nicoderm CQ), 1mg nicotine nasal spray, placebo nasal spray; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: AIDS
Interventions: GSK Biologicals HIV Vaccine 732462, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 17
States / cities: Bakersfield, California • Long Beach, California • Washington D.C., District of Columbia + 13 more

Conditions: Primary Hyperoxaluria
Interventions: DCR-PHXC, Placebo; Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 6 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cervical Insufficiency
Interventions: Azithromycin Prophylaxis, Azithromycin Placebo, Cefazolin, Progesterone; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Oak Lawn, Illinois • Park Ridge, Illinois

Conditions: Opioid Use, Enhanced Recovery After Surgery, Anesthesia, Ketamine, Pain, Postoperative
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Analgesic Adverse Reaction
Interventions: Ketorolac Tromethamine, 0.9% Normal Saline; Drug
Lead sponsor: Albany Medical College; Other
Eligibility: 2 Years to 18 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Albany, New York

Conditions: Dengue
Interventions: Placebo (SC), Placebo (ID), Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID); Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Mechanical Ventilation, Pediatric Acute Respiratory Failure, Analgesics, Opioid, Sedation and Analgesia
Interventions: Acetaminophen, Ketorolac, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 2 Months to 17 Years
Enrollment: 644 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Ann Arbor, Michigan + 13 more

Conditions: Acute Myeloid Leukaemia (AML)
Interventions: Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.; Drug
Lead sponsor: Moleculin Biotech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Augusta, Georgia + 5 more

Conditions: Polycythemia Vera
Interventions: SLN124, Placebo; Drug
Lead sponsor: Silence Therapeutics plc; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 5
States / cities: Hammond, Louisiana • Buffalo, New York • New York, New York + 2 more

Conditions: Cutaneous Leiomyomas, Hereditary Leiomyomatosis and Renal Cell Cancer
Interventions: Botulinum toxin type A, Placebo; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Hyperinsulinism
Interventions: Exendin-(9-39), Vehicle; Drug · Other
Lead sponsor: Diva De Leon; Other
Eligibility: 7 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Atopic Asthma
Interventions: abatacept, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cervical Dystonia
Interventions: ABP-450, Placebo; Drug
Lead sponsor: AEON Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 17 more

Conditions: Major Depressive Disorder, Surgery, Orthopedic Disorder
Interventions: Ketamine, Normal saline (placebo); Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: Ciraparantag, Placebo, Point-of-Care Coagulometer (investigational device); Drug · Device
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas

Conditions: Contact Lens Solution
Interventions: Tangible Boost, Placebo saline; Device · Other
Lead sponsor: Tangible Science; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Hepatocellular
Interventions: Mapatumumab, Placebo, Sorafenib; Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 9
States / cities: Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more

Conditions: Nonalcoholic Steatohepatitis, NASH
Interventions: ALN-HSD, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more

Conditions: Kidney Cancer, Prostate Cancer
Interventions: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution, 0.9% Sodium Chloride Injection; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbia, Missouri

Search by objective public record fields.

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT

Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy

Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons

Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

Azithromycin for Cerclage Prophylaxis

The Impact of Perioperative Ketamine Infusion on Surgical Recovery

Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy

Tetravalent Chimeric Dengue Vaccine Trial

Optimizing Pain Treatment in Children On Mechanical Ventilation

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

Study to Assess SLN124 in Patients With Polycythemia Vera

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic Asthmatics

A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia

Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery

Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults

Evaluation of Tangible Boost Replenishing System

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery